Dermatology Practical & Conceptual

Supplementary material

Table S1. Patient-Oriented Eczema Measure (POEM).

AD symptoms	Frequency of occurrence n (%), N=61				
	Any day	**1-2 days**	**3-4 days**	**5-6 days**	**Every day**
Itching	0 (0.0)	2 (3.3)	5 (8.2)	2 (3.3)	52 (85.2)
Sleep disturbances	6 (9.8)	8 (13.1)	12 (19.7)	11 (18.0)	24 (39.3)
Skin bleeding	8 (13.1)	10 (16.4)	8 (13.1)	12 (19.7)	23 (37.7)
Eczema dampens or wets clothes	24 (40.0)	8 (13.3)	9 (15.0)	6 (10.0)	13 (21.7)
Cracked skin	4 (6.6)	10 (16.4)	8 (13.1)	10 (16.4)	29 (47.5)
Peeled skin	6 (9.8)	7 (11.5)	8 (13.1)	6 (9.8)	34 (55.7)
Dry or rough skin	0 (0.0)	3 (5.0)	4 (6.7)	4 (6.7)	49 (81.7)

AD: atopic dermatitis; n: patients with an event; N: number of patients with available data.

Table S2. EQ-5D-3L in Patients with AD.

EQ dimensions	Patients in each EQ level n (%), N=57		
	No problems	**Some problems**	**Extreme problems**
Mobility	47 (82.5)	9 (15.8)	1 (1.8)
Self-care	43 (75.4)	13 (24.6)	0 (0.0)
Daily activities	35 (61.4)	22 (38.6)	0 (0.0)
Pain/discomfort	15 (26.3)	26 (45.6)	16 (28.1)
Anxiety/depression	24 (42.1)	27 (47.4)	6 (10.5)
Total EQ-D5-3L VAS, mean (SD)	55.6 (22.5)		

EQ-5D-3L: 3-level version of the 5-dimension EuroQuol index; n: patients with an event; N: number of patients with available data.

Table S3. Treatment Patterns for Special Body Areas Affected by AD.

Study parameter	At study visit (in the two weeks before the visit)	After the visit (planned)
Patients with treatment for special body areas affected by AD, n (%) [N]	10 (17.5) [57]	11 (17.7) [62]
Body areas affected, n (%) [N]		
Face	5 (50.0) [10]	7 (63.6) [11]
Periorbital	3 (30.0) [10]	3 (27.3) [11]
Folds	1 (10.0) [10]	3 (27.3) [11]
Neck	0 (0.0) [10]	3 (27.3) [11]
Perioral	0 (0.0) [10]	1 (9.1) [11]
Other	1 (10.0) [10]	2 (18.2) [11]
Treatment used¥, n (%) [N]		
Topical calcineurin inhibitors	4 (40.0) [10]	10 (90.9) [11]
Topical corticosteroids	4 (40.0) [10]	9 (81.8) [11]
Emollients	3 (30.0) [10]	0 (0.0) [11]

AD: atopic dermatitis; n: patients with an event; N: number of patients with available data.

¥Multiple response. Percentages can add up to more than 100%

Table S4. Utilization of Healthcare Resources.

Study parameter	Value Mean (SD) [N]
Number of AD-related visits to the pharmacy in the last year	12.4 (13.4) [49]
Number of visits to hospitals/specialized centers in the last year	2.7 (3.1) [57]
Number of hospitalizations in the last year	0.0 (0.0) [58]
Overall number of hospitalizations	0.2 (0.6) [58]
Number of AD-related ED visits in the last year	0.7 (1.1) [58]
Overall number of ED visits due to AD	2.6 (7.2) [53]

AD: atopic dermatitis; ED: emergency department; n: patients with an event; N: number of patients with available data; SD: standard deviation.

Table S5. Complementary Diagnostic Tests.

Diagnostic test	Performed in the past n (%) [N]	Planned after the visit n (%) [N]
Total IgE	25 (40.3) [62]	34 (54.8) [62]
IgE specific for allergens	15 (24.2) [62]	10 (16.1) [62]
Skin tests	20 (32.8) [61]	8 (12.9) [62]
Prick test	13 (65.0) [20]	2 (25.0) [8]
Patching tests	10 (50.0) [20]	7 (87.5) [8]

Ig: immunoglobulin; n: patients with an event; N: number of patients with available data.

Table S6. Healthcare Costs Borne by Patients with AD.

Study parameter	Value
Cost of patient displacement to receive healthcare assistance in the last month (€), median (IQR) [N]	10.0 (4.5-20.0) [33]
Cost of acquiring products to better control AD (€), n (%), N=53	
0	11 (20.8)
1 – 50	15 (28.3)
51 – 100	10 (18.9)
100 – 200	9 (17.0)
>200	8 (15.1)
Home care, n (%) [N]	1 (1.8) [57]
Use of alternative therapy/unlicensed products, n (%) [N]	14 (25.0) [56]
Emollients	2 (18.2) [11]
Homeopathy	2 (18.2) [11]
Acupuncture, yoga, tryptophan, omega 3, mindfulness	1 (9.1) [11]
Creams and ointments	1 (9.1) [11]
Parapharmacy creams, soaps	1 (9.1) [11]
Salt caves	1 (9.1) [11]
Natural supplements	1 (9.1) [11]
Natural therapy: herbal infusions	1 (9.1) [11]
Cost of alternative therapy/products in the last year (€), mean (SD) [N]	132.9 (148.9) [12]
Cost of emollients in the last month (€), mean (SD) [N]	40.1 (30.5) [38]

AD: atopic dermatitis; n: patients with event; N: number of patients with available data; SD: standard deviation.